Comments

I-MAB Stock Price, Quotes and Forecasts

Q: What sector and industry does I-MAB (IMAB) operate in?

I-MAB is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

IMABNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.6888

At close: Apr 10 EDT

$0.6888

0.000.00%

Pre-Market: 7:36 AM EDT

FY 2024 Earnings were released on Thu Apr 3rd, after the market close

I-MAB (IMAB) Forecast

News Earnings I-MAB (IMAB) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

I-MAB Stock Price, Quotes and Forecasts | NASDAQ:IMAB | Benzinga

Explore I-MAB stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IMAB.

Open	-
Close	-
Volume / Avg.	2.71K / 262.30K
Day Range	- - -
52 Wk Range	0.60 - 2.00
Market Cap	$55.71M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	34
Short Interest	2.88%
Days to Cover	3.46

Recent News

ADT To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Avi Kapoor

I-Mab Gets New CEO After Long Search. Sale Of The Company Coming Next?

Key Takeaways: I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hinting that I-Mab could follow a similar path By Warren Yang

The Bamboo Works

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	2.71K / 262.30K
Day Range	- - -
52 Wk Range	0.60 - 2.00
Market Cap	$55.71M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	34
Short Interest	2.88%
Days to Cover	3.46

About I-Mab

Sector

Health Care

Industry

Biotechnology

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in...

Got Questions? Ask

Analyze IMAB's market performance

How has IMAB's EPS changed?

How is IMAB's operating margin?

What is IMAB's current market cap?

What is IMAB's operating cash flow?

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy I-MAB (IMAB) stock?

You can purchase shares of I-MAB (NASDAQ:IMAB) through any online brokerage.

View our list of the best stock brokerages

Who are I-MAB (IMAB) competitors?

Other companies in I-MAB’s space includes: Serina Therapeutics (AMEX:SER), Cabaletta Bio (NASDAQ:CABA), bluebird bio (NASDAQ:BLUE), Inozyme Pharma (NASDAQ:INZY) and Inovio Pharmaceuticals (NASDAQ:INO).

What is the forecast, or price target, for I-MAB (IMAB) stock?

I-MAB has a consensus price target of $11.50.

What is the current price for I-MAB (IMAB)?

The stock price for I-MAB (NASDAQ: IMAB) is $0.6888 last updated April 10, 2025 at 7:36 AM EDT.

Does I-MAB (IMAB) pay a dividend?

There are no upcoming dividends for I-MAB.

When is I-MAB (NASDAQ:IMAB) reporting earnings?

I-MAB’s FY earnings are confirmed for Thursday, April 3, 2025.

Is I-MAB (IMAB) going to split?

There is no upcoming split for I-MAB.

What sector and industry does I-MAB (IMAB) operate in?

I-MAB is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.